Purchase 4F-PV9
Discount program, second-order - 5% OFF, third order - 7% OFF
With us securely! - re-shipment guarantees.
We always offer new legal products of impeccable quality.
Please make sure that the product is legal in your country and not under control before ordering.
We do not sell pharmaceutical products or controlled products.
Where to buy 4F-PV9 for sale
4'-Fluoro-α-pyrrolidinooctanophenone, also known as 4-fluoro-α-PPP, is a synthetic stimulant drug reported as a novel designer drug.
4'-Fluoro-α-pyrrolidinooctanophenone is a stimulant drug of the cathinone class.
4'-Fluoro-α-pyrrolidinooctanophenone (also known as "Flakka") is a synthetic stimulant of the cathinone class.
4-Fluoro-α-pyrrolidinooctanophenone (also known as 4-fluoro-PV9) is an emerging designer drug of the cathinone class. It is generally similar in structure to the common stimulant cathinone but has a fluorine atom attached to its α carbon. The IUPAC name of this compound is 2-(4'-fluorophenyl)-1-(pyrrolidin-1-yl) pentane-1-one, with an empirical formula C15H18FNOP and a molecular weight of 260.325 g/mol.
4-Fluoro-α-pyrrolidinooctanophenone (also known as 4-fluoro-PV9) is an emerging designer drug of the cathinone class.
4-Fluoro-α-pyrrolidinooctanophenone is a psychotropic substance of the phenylalanine class and a structural analog of α-pyrrolidinobutiophenone.
4-Fluoro-PV9 is a chemical compound with an empirical formula C15H18FNOP and a molecular weight of 260.325 g/mol.
4-Fluoro-PV9 is a designer stimulant that can be taken in pill or powder form.
4-Fluoro-PV9 is a novel designer drug with stimulant and entactogen properties. The psychoactive effects of 4-Fluoro-PV9 are similar to those of other NPS. The inhibition of monoamine reuptake that produces the euphoric, stimulating and hallucinogenic effects are mediated by its action on dopamine transporters (DAT), norepinephrine transporters (NET) and serotonin transporters (SERT).
4-Fluoro-PV9 is a novel designer drug with stimulant and entactogenic properties.
4-Fluoro pyrrolidinone PV9 (4F-PV9) is a novel designer drug with stimulant and entactogen properties. It can be addictive and can cause health problems.
4-Fluoro-PV9 is a designer drug that can boost energy and increase feelings of happiness.
We are a novel designer drug with stimulant and entactogen properties, created to provide you with euphoria, stimulation, and hallucinations.
4-Fluoro-PV9 is a designer drug often found on the dance scene.
Like many drugs and supplements, the exact effects of 4-Fluoro-PV9 are not fully understood. Research on its uses is in progress.
4'-Fluoro-α-pyrrolidinooctanophenone (also known as 4-Fluoro-PV-9, FPOP and 4-Fluoro-α-POP), is an analog of α-pyrrolidinobutyrophenone (α‐PBP). 4'-Fluoro-α‐pyrrolidinooctanophenone has been found as an active compound in many samples of "bath salts" sold in Japan and Norway.
4'-Fluoro-PV-9 is an analog of α-pyrrolidinobutyrophenone (α‐PBP). It has been found in many "bath salt" samples.
4'-Fluoro-α-pyrrolidinooctanophenone (4-fluoro-PV9) is a new psychoactive substance structurally related to a series of synthetic stimulants commonly sold as "bath salts."
4-Fluoro-PV-9 is an analog of alpha-pyrrolidinobutyrophenone. (See also entries for pyrrolidinopentiophenone, α-PBP, and PV-9.)
FPOP is a pyrrolidinophenone-based stimulant. FPOP has been found in "bath salt" products recently and has been the subject of several studies which have reported it to cause euphoria, disinhibition and intense hallucinations (particularly auditory hallucinations) with limited hallucinogenic effects.
4'-fluoro-α-pyrrolidinooctanophenone (4F-PV9) is an emerging drug of abuse that can induce similar behavioral and physiologic effects observed in stimulant intoxication and, in some cases, dependence.
Objective: The neuropsychopharmacological effects of 4'-fluoro-α-pyrrolidinooctanophenone (FPOP) have not yet been fully investigated and reported. This study sought to characterize the neurochemical profiles of FPOP-induced behaviors in rats.
To prepare the content, the following materials were used:
- FDA Substance Registration System
- Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014. 3,4-Methylenedioxymethamphetamine
- Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. PDF . By HoChong Gilles, Scott C Matherly, Mohammed S Siddiqui, Puneet Puri...
- Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis . By Jasmohan Bajaj
- An overview of alcohol and other drug issues
- Medicating the mind: a Kantian analysis of overprescribing psychoactive drugs B A Manninen
- The pharmacological basis of opioids Carla Ghelardini, Lorenzo Di Cesare Mannelli and Enrica Bianchi
- Ask Dr. Shulgin Online ARCHIVE: June 3, 2004
- Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Nicholas V Cozzi, Michael KSievert, Alexander T Shulgin, Peyton JacobIII, Arnold Eruoho
- Schedules of Controlled Substances: Placement of Methylone Into Schedule I
- Bioanalysis of new designer drugs. Wohlfarth A, Weinmann W.
- New Psychoactive Substances (including synthetic cannabinoids, mephedrone, and more)
- Future Synthetic Drugs of Abuse. Donald A. Cooper. Drug Enforcement Administration McLean, Virginia
- Designer drugs: a medicinal chemistry perspective. F. Ivy Carroll Anita H. Lewin S. Wayne Mascarella Herbert H. Seltzman P. Anantha Reddy
- Synthetic cannabinoids in Europe
- Pharmacological Effects of MDMA in Man. By Enno Freye
- Drug Use in Relation to Outcome of Mammography Screening. von Euler-Chelpin M, Wu W, Vejborg and Lynge E
- DEA Drug Scheduling
- Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons.Ada Ledonne, Nicola Berretta, Alessandro Davoli, Giada Ricciardo Rizzo, Giorgio Bernardi and Nicola Biagio Mercuri
- Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons.Scarponi M, Bernardi G, Mercuri NB.
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. Henry A. Spiller, author Hannah L. Hays Alfred Aleguas.
- Dose-dependent effectiveness of wheel running to attenuate cocaine-seeking: impact of sex and estrous cycle in rats. Peterson AB, Hivick DP, Lynch WJ.r.
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
- Controlled Substances Act
- The Art of Drug Synthesis (Wiley Series on Drug Synthesis)
- Cannabis: domestic cultivation widespread
- A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics
100g $550
out of stock
out of stock
out of stock
1kg $1690
100g $390
1kg $1590
500g $1700
1000 pills $45
out of stock
1kg $1690